Literature DB >> 25693021

First-line crizotinib in ALK-positive lung cancer.

Benjamin J Solomon, Tony Mok.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25693021     DOI： 10.1056/NEJMc1415973

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  (J)ALEX the great: a new era in the world of ALK inhibitors.

Authors:  Solenn Brosseau; Valérie Gounant; Gérard Zalcman
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.

Authors:  Marissa S Mattar; Jason Chang; Ryma Benayed; Darragh Halpenny; Astin Powers; David E Kleiner; Alexander Drilon; Mark G Kris
Journal:  Clin Lung Cancer       Date:  2019-10-13       Impact factor: 4.785

3.  Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

Authors:  Takayuki Kosaka; Junko Tanizaki; Raymond M Paranal; Hideki Endoh; Christine Lydon; Marzia Capelletti; Claire E Repellin; Jihyun Choi; Atsuko Ogino; Antonio Calles; Dalia Ercan; Amanda J Redig; Magda Bahcall; Geoffrey R Oxnard; Michael J Eck; Pasi A Jänne
Journal:  Cancer Res       Date:  2017-03-31       Impact factor: 12.701

4.  The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.

Authors:  Tejas Patil; Derek E Smith; Paul A Bunn; Dara L Aisner; Anh T Le; Mark Hancock; William T Purcell; Daniel W Bowles; D Ross Camidge; Robert C Doebele
Journal:  J Thorac Oncol       Date:  2018-07-05       Impact factor: 15.609

5.  Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study.

Authors:  S Kayaniyil; M Hurry; J Wilson; P Wheatley-Price; B Melosky; J Rothenstein; V Cohen; C Koch; J Zhang; K Osenenko; G Liu
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

6.  Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers.

Authors:  De-Ning Ma; Xin-Yi Gao; Yi-Bo Dan; An-Ni Zhang; Wei-Jun Wang; Guang Yang; Hong-Zhou Zhu
Journal:  Onco Targets Ther       Date:  2020-07-16       Impact factor: 4.147

7.  Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report.

Authors:  Shuluan Li; Pei Zhang; Tianyu Wang; Jie Wang; Jianchun Duan
Journal:  Thorac Cancer       Date:  2021-10-13       Impact factor: 3.500

8.  Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Authors:  I Watermann; B Schmitt; F Stellmacher; J Müller; R Gaber; Ch Kugler; N Reinmuth; R M Huber; M Thomas; P Zabel; K F Rabe; D Jonigk; A Warth; E Vollmer; M Reck; T Goldmann
Journal:  Diagn Pathol       Date:  2015-07-28       Impact factor: 2.644

9.  Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement.

Authors:  Yuko Oya; Hiroaki Kuroda; Takeo Nakada; Yusuke Takahashi; Noriaki Sakakura; Toyoaki Hida
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.